Clinical Trial Update: A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial of AK112, a PD1/VEGF bispecific, in combination with chemotherapy for non-small cell lung cancer; currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AK112

Snippet

Sponsor: Akeso | Conditions: NSCLC | Phase 2 | Status: ACTIVE_NOT_RECRUITING